DONQ 52
Alternative Names: DONQ-52Latest Information Update: 11 Aug 2022
At a glance
- Originator Chugai Pharmaceutical
- Class Bispecific antibodies
- Mechanism of Action HLA-DQ antigen inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Coeliac disease
Most Recent Events
- 14 Aug 2022 Phase-I clinical trials in Coeliac disease in USA (SC) (NCT05425446)
- 23 Jun 2022 Chugai Pharmaceutical plans a phase I LILY trial for Coeliac disease (SC) in July 2022 (NCT05425446)
- 01 Jun 2022 Preclinical trials in Coeliac disease in Japan (SC)